West Africa may not seem likely the location for the�next big gold mining rush for investors in small cap gold stocks, but a couple of small caps in the West Africa mining space have been reporting progress this month.
Just today, small cap Avesoro Resources (OTCMKTS: ARSMF; TSE: ASO) announced production results for the quarter ended March 31,�2017 from its New Liberty Gold Mine in Liberia. The quarter saw continued improvement in both mining and processing operations as management continues the turnaround in operations at New Liberty. Total gold production for the Quarter was 14,906 ounces (as previously guided) while�full year production guidance of 90,000 �� 100,000 ounces�was maintained as is previously advised cash cost guidance of US$750 �� US$800 per ounce and all in sustaining costs (��AISC��) guidance of US$925 �� US$975 per ounce of gold produced. The CEO commented:
Best Small Cap Stocks To Watch Right Now: Aerosonic Corporation(AIM)
Advisors' Opinion:- [By Shane Hupp]
Aimia (TSE:AIM) has earned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is C$2.67.
Best Small Cap Stocks To Watch Right Now: Potash Corporation of Saskatchewan Inc.(POT)
Advisors' Opinion:- [By Joseph Griffin]
PotCoin (CURRENCY:POT) traded 0.6% higher against the US dollar during the 24 hour period ending at 23:00 PM E.T. on May 12th. PotCoin has a total market capitalization of $23.95 million and approximately $62,522.00 worth of PotCoin was traded on exchanges in the last 24 hours. During the last seven days, PotCoin has traded 17.8% lower against the US dollar. One PotCoin coin can now be purchased for approximately $0.11 or 0.00001293 BTC on popular cryptocurrency exchanges including Cryptopia, CoinExchange, Trade By Trade and Tux Exchange.
- [By Ethan Ryder]
Headlines about Potash Co. of Saskatchewan (NYSE:POT) (TSE:POT) have trended positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Potash Co. of Saskatchewan earned a news impact score of 0.43 on Accern’s scale. Accern also gave media coverage about the fertilizer maker an impact score of 45.4285202328488 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Best Small Cap Stocks To Watch Right Now: Merck & Company, Inc.(MRK)
Advisors' Opinion:- [By Chris Lange]
The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 22.95 million from 23.67 million in the previous period. Its shares were trading at $60.09, in a 52-week range of $52.83 to $66.41.
- [By Keith Speights]
First, BMS won Food and Drug Administration (FDA) approval for a new dosing schedule for Opdivo on March 6. This change allows physicians to administer Opdivo to patients every four weeks instead of every two weeks for most of the approved indications for the drug. In addition, Opdivo was approved for a shorter 30-minute infusion for all approved indications. Opdivo now enjoys an advantage related to patient convenience that Merck's (NYSE:MRK) Keytruda doesn't.
- [By Shane Hupp]
WARNING: “Brokerages Set Merck & Co. (MRK) Target Price at $66.13” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3356646/brokerages-set-merck-co-mrk-target-price-at-66-13.html.
- [By Keith Speights]
All three of these apply to Pfizer (NYSE:PFE), but they also all apply to Merck (NYSE:MRK). Both pharmaceutical companies have successful�products with sizzling sales, but both have experienced headwinds that have weighed on their�overall revenue and earnings growth.�
- [By Paul Ausick]
Merck & Co Inc. (NYSE: MRK) traded up 2.60% at $58.65. The stock’s 52-week range is $52.83 to $66.41. Volume was about 45% above the daily average of around 13.3 million. The company’s lung cancer drug is distancing itself from contenders.
No comments:
Post a Comment